Bold Brandicourt Plots Mega Sanofi And Boehringer Animal, Consumer Asset Swap

Sanofi and Boehringer Ingelheim are in exclusive negotiations to swap parts of their businesses. The deal would involve an exchange of Sanofi's animal health business Merial, which is worth €11.4bn, with Boehringer's consumer healthcare (CHC) business, worth €6.7bn. To make up the difference in value between the two businesses, Boehringer would make a cash payment to Sanofi of €4.7bn.

Sanofi and Boehringer Ingelheim are in exclusive negotiations to swap parts of their businesses. The deal would involve an exchange of Sanofi's animal health business Merial, which is worth €11.4bn, with Boehringer's consumer healthcare (CHC) business, worth €6.7bn. To make up the difference in value between the two businesses, Boehringer would make a cash payment to Sanofi of €4.7bn.

Privately held Boehringer's CHC business in China is excluded from the discussions.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category